Buy Cagrilintide 5mg + Semaglutide 5mg

Core Mechanisms

• Semaglutide (GLP-1 Receptor Agonist): Mimics the glucagon-like peptide-1 hormone to slow gastric emptying, stimulate insulin, and signal fullness to the brain.
• Cagrilintide (Long-acting Amylin Analogue): Mimics amylin, a pancreatic hormone co-secreted with insulin that enhances satiety and further delays stomach emptying. 

Clinical Efficacy (2025/2026 Data) 

• Weight Loss: In Phase III trials (REDEFINE 1), participants without diabetes achieved an average of 20% to 23% body weight reduction over 68 weeks.
• Diabetes Management: For those with type 2 diabetes, the combination showed weight loss of approximately 16% and substantial improvements in HbA1c levels compared to either drug alone.
• Cardiovascular Benefits: Studies noted improvements in blood pressure, lipid levels, and waist circumference 

Dosage and Status

• Official Maintenance Dose: In official clinical trials (CagriSema), the target maintenance dose is typically 2.4mg of each component once weekly.
• Research Peptides: The “5mg + 5mg” configuration is frequently found in the research peptide market (often as lyophilized powder for reconstitution) but is not currently a standard FDA-approved medical prescription dose.
• Availability: Novo Nordisk is expected to submit CagriSema for FDA approval in early 2026, potentially making it commercially available by late 2026.